At the EmTech China Global Emerging Technology Summit held from July 29th to 30th, biomedicine became a hot topic.
What are the new characteristics of biomedical research and application in my country, and what new breakthroughs have been made?
In the next step, what aspects will be used to promote the transformation and application of innovative achievements?
Experts and scholars from scientific research institutions and enterprises conducted in-depth discussions on the current status of biomedical technology and applications, as well as future development trends, and put forward a series of new viewpoints and directions.
Experts suggest that the new crown vaccine should be upgraded from "three defenses" to "five defenses"
"In the past two years or so, all mankind has encountered an extremely dangerous new crown pneumonia epidemic. In the response to the epidemic, science and technology have played a very important role." At the Global Emerging Technology Summit, the Chinese Academy of Sciences Gao Fu, an academician and a researcher at the Institute of Microbiology of the Chinese Academy of Sciences, believes that one of the keys to our country's ability to take the path of fighting against the new crown pneumonia epidemic is that due to scientific and technological progress, the people and policy makers have a good understanding of the prevention and control of the new crown.
"Humanity is going through a race against viruses. I was one of the first scientific research disease control managers to participate in the handling of the new crown pneumonia epidemic, and we quickly sequenced the whole genome. In less than a week, we and the world's Scientists shared data and began to develop vaccines, from inactivated vaccines to mRNA vaccines to adenovirus vector vaccines, and developed protein drinks and other related achievements." Gao Fu introduced.
Wei Yuquan, academician of the Chinese Academy of Sciences and former vice president of Sichuan University, believes that at present, the new crown virus is still prevalent in the world, and the research and development of vaccines is always the top priority in defeating the epidemic.
In the next stage, the research and development goals of the new crown vaccine should be upgraded from the "three defenses" of preventing disease, severe illness, and preventing death to focusing on "five defenses" such as infection prevention and transmission prevention.
"Our team has been engaged in the research and development of various new vaccine technologies for infectious diseases, tumors and other major diseases. Among them, the histone new crown vaccine is already in the third phase of clinical trials. From the results, it has a positive effect on Omicron infection. It has a very good protective effect and high safety. At present, our team is developing a general-purpose next-generation new crown vaccine to prevent infection and spread." Wei Yuquan said.
Wei Yuquan introduced that the "14th Five-Year Plan for Bio-economic Development" issued by the National Development and Reform Commission in May this year clarified the specific tasks of bio-economic development. In the field of public health planning, it is required to adapt to the new trend of passive defense to active protection. In the future, it will strengthen the capacity building of prevention, control and treatment of major emerging and emergent infectious diseases, animal and plant epidemic diseases, accelerate the iterative upgrade of vaccine research and development and production technology, develop multiple vaccines, and develop new genetically engineered vaccines, therapeutic Vaccines to improve the ability to respond to major viscous infectious diseases.
The main role of infectious disease vaccines is to prevent infection, prevent transmission, prevent disease, prevent severe disease and prevent death.
Guided by clinical value, guiding the future of drug innovation
"In the past few years, domestic innovations have yielded fruitful results. A number of domestic innovative drugs with different technical routes have been launched, and the price is far lower than that of international similar products, which has unprecedentedly met the huge clinical needs of my country and greatly promoted the The innovation enthusiasm of all parties in my country." said Jia Xiangbo, founder and chairman of Zhikang Hongyi.
He introduced that Chinese patients have benefited enormously from biomedical innovation.
Judging from the products that have been listed, including small molecules, monoclonal antibodies, double antibodies, ADC, CAR-T and other modern technology forms, as well as a variety of products involving various advanced technology routes of RNA gene and cell therapy, are in the process of in clinical development.
Guided by clinical value, it is becoming the fundamental guideline for the future of drug innovation.
Last year, the Drug Evaluation Center of the State Drug Administration issued relevant documents oriented by clinical value, which pointed out the direction for the development of the industry. This is an important turning point and wind vane for guiding innovation to return to clinical value. In the future, the new drug industry will further focus on scientific, Clinical and commercial to create real value.
"At present, we have seen that the R&D capabilities of local enterprises are gradually increasing, and our international influence is constantly growing. The authorization of products by Chinese companies overseas is the best proof of the R&D capabilities of enterprises. The number of overseas authorizations in the first half of this year exceeded that of last year. , which allows us to see great hope for the future of China's biotechnology." Jia Xiangbo said.
Insilicon founder and CEO Alex Zhavoronkov believes that the use of next-generation artificial intelligence has become a new way of drug discovery.
Traditionally, drug discovery takes decades because targets are hard to find.
Artificial intelligence technology can shorten the time required and increase the probability of successful drug development.
In Jia Xiangbo's view, in the face of constant changes in the industry, only innovation is eternal, and the biopharmaceutical industry has a specific performance in a specific time period. From a long-term perspective, my country's biopharmaceutical innovation is in the ascendant and the future can be expected. Flourish.